Astepro Launch And Strong Cold Season Boost Bayer In Q3

The US OTC launch of reclassified nasal spray Astepro Allergy, in combination with “continuously elevated cold incidence rates,” helped to drive up Bayer's Consumer Health sales at a double-digit rate in Q3.

• Source: Alamy

Launching Astepro Allergy in the US following a successful Rx-to-OTC switch helped Bayer Consumer Health’s Allergy & Cold category post a double-digit rise in sales in the third quarter.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

More from Business